Pipeline

Crenessity@

CRENESSITY Capsule 50/100 MG $766.66

packaging 50 MG 60u $45,999.60

packaging 100 MG 30u. Starts at approximately $21,338.71 USD for a monthly supply

Ingrezza@

Ingrezza (valbenazine) As of July 2025, the average pharmacy acquisition cost for Ingrezza capsules in the U.S. is approximately:

$274.54 per capsule for the 60 mg and 80 mg strengths
$250.16 per capsule for the 40 mg strength

Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88

Assumptions

Risks

Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.
Risks related to the development of product candidates.
Risks associated with dependence on third parties for development, manufacturing, and commercialization activities for products and product candidates, and ability to manage these third parties.
Risks that the FDA or other regulatory authorities may make adverse decisions regarding products or product candidates.
Risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials.
Risks that the potential benefits of the agreements with collaboration partners may never be realized.
Risks that products, and/or product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse.
Risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on products or limit coverage and/or reimbursement for products.
Risks associated with competition from other therapies or products, including potential generic entrants for products; constraints, volatility, or disruptions in the capital markets or other factors affecting ability to complete an accelerated share repurchase transaction; and other risks described in periodic reports filed with the Securities and Exchange Commission.

Neurocrine Biosciences is set to achieve a 40x future PE ratio with a 17% revenue boost

Shared on26 Jul 25Fair value Increased 59%

Shared on26 Jul 25
Fair value Increased 59%